Company / Financials
NRX Pharmaceuticals, Inc. Financials
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025
Net Income
-$25.1M
FY2025 · +16.7% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$13.0M
FY2025
Total Debt
-
FY2025
Equity
-$23.2M
FY2025
ROA
-193.9%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -5.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$25.1M+16.7% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$0Operating Income HistoryProfit from core business operations before interest and taxes-$18.5M+33.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$13.5M-5.0% YoYR&D Expense HistoryResearch and development spending$6.2M-53.6% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$2.36+40.7% YoYShares Outstanding HistoryWeighted average diluted shares outstanding14.6M+73.9% YoYTotal Assets HistoryTotal value of all assets owned$13.0M+254.9% YoY